scholarly journals Comparison of two equivalent model for end-stage liver disease scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry

2017 ◽  
Vol 30 (11) ◽  
pp. 1098-1109 ◽  
Author(s):  
Sarah K. Alver ◽  
Douglas J. Lorenz ◽  
Kenneth Washburn ◽  
Michael R. Marvin ◽  
Guy N. Brock
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Liver Transplant ◽  
Waiting List ◽  
Equivalent Model ◽  
End Stage Liver Disease ◽  
Using Data ◽  
Liver Transplant Waiting List ◽  
End Stage ◽  
United Network

339 Outcomes of Patients With END-Stage Liver Disease on Dialysis for More Than 6 Weeks on the Liver Transplant Waiting List

2010 ◽  
Vol 138 (5) ◽  
pp. S-784
Author(s):  
Ayse L. Mindikoglu ◽  
Laurence S. Magder ◽  
Stephen L. Seliger ◽  
Jean-Pierre Raufman ◽  
Charles D. Howell
Keyword(s):  
Liver Disease ◽  
Liver Transplant ◽  
Waiting List ◽  
End Stage Liver Disease ◽  
Liver Transplant Waiting List ◽  
End Stage

Validation of the five-variable Model for End-stage Liver Disease (5vMELD) for prediction of mortality on the liver transplant waiting list

2013 ◽  
Vol 34 (8) ◽  
pp. 1176-1183 ◽  
Author(s):  
Robert P. Myers ◽  
Puneeta Tandon ◽  
Michael Ney ◽  
Glenda Meeberg ◽  
Peter Faris ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Transplant ◽  
Waiting List ◽  
Variable Model ◽  
End Stage Liver Disease ◽  
Prediction Of Mortality ◽  
Liver Transplant Waiting List ◽  
End Stage

Survival Before and After Model for End-stage Liver Disease Score Introduction on the Brazilian Liver Transplant Waiting List

2010 ◽  
Vol 42 (2) ◽  
pp. 412-416 ◽  
Author(s):  
R.S. Castro ◽  
D. Deisanti ◽  
T. Seva-Pereira ◽  
J.R.S. Almeida ◽  
A. Yamanaka ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Transplant ◽  
Waiting List ◽  
Disease Score ◽  
End Stage Liver Disease ◽  
Before And After ◽  
Liver Transplant Waiting List ◽  
End Stage

scholarly journals Excess mortality on the liver transplant waiting list: Unintended policy consequences and model for End-Stage Liver Disease (MELD) inflation

Hepatology ◽  
2014 ◽  
Vol 61 (1) ◽  
pp. 285-291 ◽  
Author(s):  
Patrick Grant Northup ◽  
Nicolas Michael Intagliata ◽  
Neeral Lalit Shah ◽  
Shawn Joseph Pelletier ◽  
Carl Lansing Berg ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Transplant ◽  
Excess Mortality ◽  
Waiting List ◽  
End Stage Liver Disease ◽  
Liver Transplant Waiting List ◽  
End Stage

scholarly journals Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients

Oncology ◽  
2020 ◽  
Vol 98 (12) ◽  
pp. 836-846
Author(s):  
Reham Abdel-Wahab ◽  
Manal M. Hassan ◽  
Bhawana George ◽  
Roberto Carmagnani Pestana ◽  
Lianchun Xiao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Growth Factor ◽  
Meld Score ◽  
Waiting List ◽  
Survival Prediction ◽  
Insulin Like Growth Factor ◽  
Priority Assignment ◽  
End Stage Liver Disease ◽  
End Stage

<b><i>Background:</i></b> Liver reserve affects survival in hepatocellular carcinoma (HCC). Model for End-Stage Liver Disease (MELD) score is used to predict overall survival (OS) and to prioritize HCC patients on the transplantation waiting list, but more accurate models are needed. We hypothesized that integrating insulin-like growth factor 1 (IGF-1) levels into MELD score (MELD-IGF-1) improves OS prediction as compared to MELD. <b><i>Methods:</i></b> We measured plasma IGF-1 levels in training (<i>n</i> = 310) and validation (<i>n</i> = 155) HCC cohorts and created MELD-IGF-1 score. Cox models were used to determine the association of MELD and MELD-IGF-1 with OS. Harrell’s c-index was used to compare the predictive capacity. <b><i>Results:</i></b> IGF-1 was significantly associated with OS in both cohorts. Patients with an IGF-1 level of ≤26 ng/mL in the training cohort and in the validation cohorts had significantly higher hazard ratios than patients with the same MELD but IGF-1 &#x3e;26 ng/mL. In both cohorts, MELD-IGF-1 scores had higher c-indices (0.60 and 0.66) than MELD scores (0.58 and 0.60) (<i>p</i> &#x3c; 0.001 in both cohorts). Overall, 26% of training and 52.9% of validation cohort patients were reclassified into different risk groups by MELD-IGF-1 (<i>p</i> &#x3c; 0.001). <b><i>Conclusions:</i></b> After independent validation, the MELD-IGF-1 could be used to risk-stratify patients in clinical trials and for priority assignment for patients on liver transplantation waiting list.

Sign in / Sign up

Export Citation Format

Share Document